EICHOR ● Active Not Recruiting

Dual-Modality Immunotherapy for HPV Clearance (DUAL-HPV)

Condition: Human Papillomavirus Infection · Cervical Intraepithelial Neoplasia (CIN) · Low-Grade Squamous Intraepithelial Lesions · Sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital

PhaseNA

Planned participants76

Who can joinFemale, 18 Years to 65 Years

Healthy volunteersNo

About this study

Persistent high-risk human papillomavirus infection is an important precursor of cervical cancer and related cervical lesions. This single-center, randomized, assessor-blinded, parallel-group controlled trial evaluates whether dual-modality immunotherapy consisting of an oral immunomodulator plus a vaginal ovule improves HPV clearance compared with standard supportive care. A total of 76 participants will be randomized in a 1:1 ratio. The primary outcome is HPV clearance confirmed by repeat HPV testing and cervical cytology after the 3-month treatment period. Treatment adherence and adverse events will also be monitored.

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Locations (1)

University of Health Sciences Turkey, Kartal Dr. Lütfi Kırdar City Hospital

Istanbul, Istanbul, Turkey (Türkiye)

—

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →